A 38-year-old woman with asthma is prescribed albuterol (salbutamol) 2 puffs every 4 hours. After 3 weeks of regular use, she reports that the same dose now provides less relief of bronchospasm, requiring use every 2–3 hours to maintain symptom control. Her peak flow measurements confirm reduced bronchodilation. The albuterol inhaler is functioning normally, and she has good inhaler technique. Which receptor-level mechanism best explains this loss of drug efficacy?

Explanation

## Tachyphylaxis and β₂-Adrenergic Receptor Desensitization **Key Point:** Loss of drug response with continued or repeated exposure to the same dose is called *tachyphylaxis*. In this case, chronic albuterol use causes β₂-adrenergic receptor downregulation and desensitization, reducing the drug's efficacy. ### Mechanism of Receptor Desensitization ```mermaid flowchart TD A["Chronic β₂-agonist exposure"]:::action --> B["Phosphorylation of β₂-AR by PKA"]:::action B --> C["β-arrestin binding to phosphorylated receptor"]:::action C --> D["Uncoupling from G-protein signaling"]:::outcome D --> E["Reduced cAMP generation"]:::outcome E --> F["Loss of bronchodilation"]:::urgent A --> G["Receptor internalization & degradation"]:::action G --> H["Downregulation: fewer receptors on cell surface"]:::outcome H --> F ``` ### Two-Phase Process 1. **Acute Desensitization (minutes to hours)** - Phosphorylation of the β₂-adrenergic receptor by protein kinase A (PKA) - β-arrestin binding to the phosphorylated receptor - Uncoupling from G-protein and adenylyl cyclase - Result: Reduced cAMP production despite agonist binding 2. **Chronic Desensitization (hours to days)** - Internalization of receptors via clathrin-coated pits - Receptor degradation in lysosomes - **Downregulation**: Net decrease in total β₂-adrenergic receptors on airway smooth muscle - Result: Fewer receptors available for albuterol to activate **High-Yield:** Tachyphylaxis is a receptor-level phenomenon, NOT a pharmacokinetic problem (no change in drug absorption, distribution, or metabolism). ### Clinical Correlation **Clinical Pearl:** Regular use of short-acting β₂-agonists (SABAs) for maintenance therapy causes tachyphylaxis and is associated with increased asthma mortality. Current guidelines recommend: - SABAs for *rescue* use only (as-needed) - Inhaled corticosteroids for maintenance therapy - Combination ICS + LABA (long-acting β₂-agonist) if frequent SABA use occurs **Mnemonic: PAID** — **P**hosphorylation, **A**rrestin binding, **I**nternalization, **D**ownregulation — the sequence of receptor desensitization. ### Why Other Options Are Incorrect | Option | Why Not | |--------|----------| | **Competitive inhibition by epinephrine** | Endogenous catecholamine levels do not increase with chronic albuterol use; this would not cause progressive loss of response | | **Irreversible covalent binding** | Albuterol is a reversible agonist; it does not form covalent bonds with receptors | | **Hepatic enzyme induction** | Albuterol is renally excreted unchanged; hepatic metabolism is minimal and does not change significantly | **Warning:** Do not confuse tachyphylaxis (loss of response to the same dose) with tolerance (need for higher doses to achieve the same effect). Both occur here, but the mechanism is receptor desensitization and downregulation.